Glioblastomas

Glioblastomas (GB) are the most malignant primary brain tumors with median survival of about 17 month despite extensive treatment. Molecular heterogeneity and the tumor microenvironment contribute to the challenges in treating GBs. Glioma-associated microglia and macrophages, comprising 30-50% of non-neoplastic cells in the microenvironment, play a crucial role in facilitating tumor growth and inducing tissue necrosis. However, the intricate interplay between these immune and glioma cells remains poorly understood.This study focuses on understanding the dynamic role of microglia during gliobla

…the treatment of primary brain tumors (glioblastomas; GBM). However, drug efficacy is reduced through a profound ability of GBM cells for DNA-repair and by the blood tumor barrier (BTB), which restricts intratumoral TMZ accumulation. Coherently, GBM almost invariably relapse with fatal outcome. We here show that GBM associated myeloid cells (GAM) simultaneously induce chemoresistance on the genetic and the vascular level by activating GP130 receptor signaling, which can be addressed therapeutically. After performing transcriptomic screens

WNT signaling is aberrantly activated in human tumors including gliomas. Promoter methylation and expression of WNT pathway’s negative regulators, DKK1 and DKK3, and positive, GSK3β, together with two signaling antagonists, SFRP1 and SFRP3, were investigated in human gliomas. Gliomas, paired blood and FFPE slides were collected with patients’ consents and classified according to WHO guidelines. Methylation-specific-PCR was used for promoter analyses, while immunohistochemistry and semi-quantitative score for consequent protein expressions. Different promoter methylation frequencies were observ

Alterations of N6-methyladenosine (m6A) RNA modifications are responsible for a platter of structural and functional changes in healthy and cancerous cell states. Even though several studies have linked m6A to the onset and development of tumors, very few have examined transcriptome-wide m6A landscape of long non-coding RNAs (lncRNAs) in cancerous cells, including gliomas. This work aims to explore and elucidate lncRNA m6A alterations and expression in glioma stem cells, U87-MG cells and glioma patients. We utilized four cell lines (NCH421k, NCH644, NCH690, U-87 MG), along with 16 glioblastoma